Union Bancaire Privee UBP SA decreased its stake in Danaher Co. (NYSE:DHR - Free Report) by 5.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 309,552 shares of the conglomerate's stock after selling 17,649 shares during the period. Danaher makes up 1.4% of Union Bancaire Privee UBP SA's portfolio, making the stock its 21st largest holding. Union Bancaire Privee UBP SA's holdings in Danaher were worth $63,405,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of DHR. Vanguard Group Inc. raised its holdings in shares of Danaher by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate's stock valued at $13,715,641,000 after buying an additional 315,912 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Danaher by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after acquiring an additional 315,446 shares in the last quarter. Norges Bank bought a new position in shares of Danaher in the fourth quarter valued at $2,130,740,000. Bank of New York Mellon Corp grew its stake in shares of Danaher by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate's stock valued at $1,971,609,000 after buying an additional 441,012 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Danaher by 14.3% in the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after buying an additional 992,594 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.
Danaher Trading Down 2.2%
DHR traded down $4.59 during trading hours on Friday, reaching $200.51. The company's stock had a trading volume of 3,391,410 shares, compared to its average volume of 3,489,232. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The business's 50-day moving average is $192.80 and its 200-day moving average is $211.19. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The stock has a market cap of $143.50 billion, a PE ratio of 37.98, a P/E/G ratio of 2.66 and a beta of 0.77.
Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. As a group, equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.64%. Danaher's dividend payout ratio is presently 24.85%.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group dropped their target price on Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Wolfe Research lowered their target price on Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research report on Monday, April 7th. HSBC lowered their price target on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. UBS Group decreased their target price on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Finally, The Goldman Sachs Group decreased their target price on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher currently has a consensus rating of "Moderate Buy" and an average target price of $248.17.
Get Our Latest Analysis on Danaher
Insider Buying and Selling
In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman now owns 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by insiders.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
